Mirabegron: A Beta-3 Agonist for Overactive Bladder
نویسندگان
چکیده
منابع مشابه
Persistence And Adherence With Mirabegron, A New Beta-3 Receptor Agonist, Versus Antimuscarinics In Overactive Bladder: Early Experience In Canada.
REFERENCES Editorial assistance was provided by S Sharpe PhD of SharpeCom Ltd (Midhurst, West Sussex, UK), and was funded by Astellas Pharma Canada Inc. Retrospective prescription claims data and statistical analyses were provided by IMS Brogan (IMS Health Canada Inc., Kirkland, Quebec, Canada). Team members: Kristen Reidel (Statistician), Brad Millson (Engagement Manager). The statements, find...
متن کاملMirabegron – a selective β3-adrenoreceptor agonist for the treatment of overactive bladder
Overactive bladder is a common condition that significantly impacts overall quality of life. Antimuscarinics are the current main pharmacological option for treatment; however, many patients fail to adhere to therapy due to troublesome side effects. Mirabegron is a new beta-3 adrenoreceptor agonist which causes detrusor smooth muscle relaxation and has been proposed to be effective for treating...
متن کاملMirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy.
PURPOSE To discuss the pharmacotherapeutic aspects of Mirabegron which is a first-in class novel β3 receptor agonist drug recently approved by the food and drug administration (FDA) for the treatment of overactive bladder (OAB). MATERIALS AND METHODS We conducted a computerized search of the MEDLINE/PUBMED databases with the word Mirabegron, β3 receptor agonist and overactive bladder. RESUL...
متن کامل[mirabegron--a New Drug for Treatment of Overactive Bladder].
Mirabegron is the first drug in a new class of oral therapy for overactive bladder (OAB). It is a beta-3 adrenergic agonist, a class of drugs for the first time used for the treatment of urination disorders. Recently, following many years of rigorous multicenter randomized trials mirabegron has been approved for use in Europe and North America. The clinical indication for mirabegron is overacti...
متن کاملEfficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
BACKGROUND Mirabegron, a β(3)-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB). OBJECTIVE To assess the efficacy and tolerability of mirabegron versus placebo. DESIGN, SETTING, AND PARTICIPANTS Multicenter randomised double-blind, parallel-group placebo- and tolterodine-controlled phase 3 trial conducted in 27 countries in Europe and Australia in patien...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Consultant Pharmacist
سال: 2014
ISSN: 0888-5109
DOI: 10.4140/tcp.n.2014.823